IGF1R and adenoma: In demonstrating EGFR blockade enhanced IGF1R activity we have provided support for the in vivo proof of concept that IGF1R-targeted therapy may induce an anti-adenoma effect in adenomas expressing high receptor levels driven by continued EGFR blockade, and is a potential predictive biomarker (Zha et al, 2009).